• Amgen stock dipped early after producing results from two recent drug studies.
  • A drug that treats atopic dermatitis appeared less useful compared with Sanofi's current drug.
  • Dow Jones sinks despite US housing stats showing better than expected New Home Sales.
  • Positive results also followed Phase 3 trial of Uplizna.

 

Amgen (AMGN) stock slid more than 4.5% at the start of Wednesday trading after the pharmaceutical giant reported the results of several drug trials.

The Dow Jones Industrial Average (DJIA), of which Amgen is a member, fell 0.4% against a backdrop of an improving NASDAQ. The DJIA has been wobbly all week.

US housing data early in the session showed that mortgage applications were rising. Additionally, New Home Sales in the US fell 4.7% MoM but were not as bad as expected.

Amgen stock news

Amgen released results from two studies late Tuesday after the market close, both of which proved positive.

First, its Phase 3 trial for Uplizna, a drug that treats IgG4-type diseases, showed an 87% reduction in IgG4-RD flare-ups. It also met all three secondary endpoints. Uplizna has been approved for treating neuromyelitis optica spectrum disorder. 

Second, its Phase 3 study of rocatinlimab, which treats atopic dermatitis, was statistically significant. Following 24 weeks of treatment, nearly 33% of patients saw at least a 75% improvement in the severity of eczema.

However, this last study was the negative issue for investors. The Sanofi-created and Regeneron-marketed Dupixent drug, which is focused on the same use case, achieved figures of 51% and 44% during its two Phase 3 studies compared with Amgen’s 33%. Hence, Amgen’s drug works but not quite as well as that of its competitors.

In reporting by industry website Fierce Biotech, Amgen Executive Vice President Murdo Gordon was not dissuaded. Gordon said that more than one drug was needed to meet the needs of patients in the atopic dermatitis market and that Amgen’s data suggested that doctors often switch prescriptions early on in treatment. Rocatinlimab’s use of a different mechanism for treatment might also persuade some physicians, according to Gordon.

Amgen stock forecast

Amgen stock is up 9.5% year to date and 24% over the past year despite dropping to $315 on Wednesday. Seeing as the pharma stock slid easily below the 100-day Simple Moving Average (SMA) on Wednesday, it could be foolish to think that the 200-day SMA might hold, which is now near $302.

If it fails to hold, then traders will look to $296, which held up earlier this summer. Below there is resistance turned support at $260, which was treated with respect throughout 2023. However, a break back above $320 would put an end to bearish sentiment.

AMGN daily stock chart

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Recommended content


Recommended content

Editors’ Picks

EUR/USD drops below 1.0700 amid renewed US Dollar demand

EUR/USD drops below 1.0700 amid renewed US Dollar demand

EUR/USD drops below 1.0700 in European trading on Monday. The pair is weighed down by the German political risks and extended US Dollar strength, as traders brace for the key US inflation data later this week. US holiday-led thin trading is likely to extend. 

EUR/USD News
GBP/USD holds lower ground near 1.2900 amid firmer US Dollar

GBP/USD holds lower ground near 1.2900 amid firmer US Dollar

GBP/USD weakens to near 1.2900 in the European session on Monday. A broadly firmer US Dollar, following Donald Trump’s US election win, continues to weigh on the pair alongside resurfacing China's economic woes and pre-US inflation report market nervousness. 

GBP/USD News
Gold price languishes near daily low amid Trump optimism-inspired USD buying

Gold price languishes near daily low amid Trump optimism-inspired USD buying

Gold price drifts lower for the second straight day and is pressured by a combination of factors. The Trump trade optimism continues to underpin the USD and weighs on the precious metal. 

Gold News
Five fundamentals: Fallout from the US election, inflation, and a timely speech from Powell stand out

Five fundamentals: Fallout from the US election, inflation, and a timely speech from Powell stand out Premium

What a week – the US election lived up to their hype, at least when it comes to market volatility. There is no time to rest, with politics, geopolitics, and economic data promising more volatility ahead.

Read more
October’s US CPI rates to be the next big test for the greenback

October’s US CPI rates to be the next big test for the greenback

With the US elections being over, Trump getting elected and the Fed having released its interest rate decision, we take a look at what next week has in store for the markets. On the monetary front a number of policymakers from various central banks are scheduled to speak at some point or the other.

Read more
Best Forex Brokers with Low Spreads

Best Forex Brokers with Low Spreads

VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.

Read More

Forex MAJORS

Cryptocurrencies

Signatures